Medical Marijuana in Canada: A Growth Industry

FDA Fast Track Designation Boosts ALS Treatment Outlook; Analyst Sees More Than 250% Upside Potential
Source: Jason Kolbert (05/12/2026)

D. Boral Capital analyst Jason Kolbert reiterated his rating and price target on Coya Therapeutics Inc. (COYA:NASDAQ) following the company's receipt of FDA Fast Track Designation for COYA 302 in ALS.

read more >

California Biotech Co. Discovers VOXZOGO Breakthrough, Reports Strong Q1
Source: Streetwise Reports (05/11/2026)

BioMarin Pharmaceuticals Inc. (BMRN:NASDAQ) delivered positive long-term achondroplasia data alongside rising revenues, accelerating rare disease portfolio growth.

read more >

Sublingual Drug Reformulator Expands into Caffeine Market and Gets Capital Injection
Source: Stewart Thomson (05/08/2026)

Technical Analyst Stewart Thomson reviews Aspire Biopharma Holdings, Inc. (ASBP:NASDAQ) in light of its recent news.

read more >

Biotech Innovator Niagen Uncovers Breakthrough NAD+ Booster, Reports Strong Q1 Results
Source: Streetwise Reports (05/08/2026)

Niagen Bioscience Inc. (NAGE:NASDAQ) reports a 3% increase in total net sales to US$31.5 million for the first quarter. Read why analysts recommend this stock in a rapidly expanding market.

read more >

FDA Rejects Melanoma Drug Again as Analysts Slash Targets and Approval Path Comes Under Fire
Source: Streetwise Reports (05/08/2026)

Replimune Group Inc. (REPL:NASDAQ) received a second FDA rejection for RP1 in advanced melanoma, prompting analyst downgrades, price target cuts, and renewed debate over approval standards for cancer therapies.

read more >